MedElevator
Войти в исследования JHEP reports : innovation in hepatology · 2026
Survival Outcomes in Hepatocellular Carcinoma: A Decade of Treatment in a Western Tertiary Referral Center.
СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
van der Meeren Pam E, Beuk Lysanne P M, Milinovic Gordana, Beijer Sverre, Bijdevaate Diederik, Den Hoed Caroline M, Dwarkasing Roy S, Eskens Ferry A L M, Franken Juliette I, Koerkamp Bas Groot, Janssen Harry, de Jonge Jeroen, van Klaveren David, Romero Alejandra Méndez, Pieterman Kay J, Polak Wojciech G, Porte Robert J, Sprengers Dave, Thomeer Maarten, Vegt Erik, Vogelaar-Tintel Naomi, Willemssen François E J A, IJzermans Jan N M, de Wilde Roeland F, Erasmus MC Hepatocellular Carcinoma Collaborative Group
Аннотация
BACKGROUND & AIMS: Hepatocellular carcinoma (HCC) remains a challenging malignancy with various available treatments. This retrospective study provides clinical outcomes on staging, treatment, and overall survival (OS) of HCC patients.
METHODS: All included patients were diagnosed between 2013 and 2022. OS was assessed using Kaplan-Meier and Cox models, stratified by BCLC stage and diagnosis period.
RESULTS: A total of 1,306 patients were analyzed: 9.1% BCLC-0, 44.3% BCLC-A, 19.1% BCLC-B, 17% BCLC-C, and 10.4% BCLC-D. Median OS (mOS) for the cohort was 19.7 months (95% CI 16.9-23.0), ranging from 86.1 months (95% CI 47.6-not reached) for BCLC-0 to 2.4 months (95% CI 1.7-3.4) for BCLC-D. Poor survival was associated with Child-Pugh (CP) classification (CP-B: HR1.49, 95% CI 1.17-1.89, CP-C: HR2.45, 95% CI 1.57-3.81), and portal vein tumor thrombosis (HR1.75, 95% CI 1.19-2.58). In 2013-2017, 609 patients (46.6%) were diagnosed with mOS of 21.7 months (95% CI 18.4-25.1), while 697 patients (53.4%) in 2018-2022 had mOS of 18.9 months (95% CI 14.8-22.7). Stratified by BCLC stage, mOS in 2013-2017 ranged from 86.1 months (95% CI 41.6-not reached) for BCLC-0 to 2.9 months (95% CI 2.2-5.7) for BCLC-D. In 2018-2022, mOS was 59.8 months (95%CI 44.2-not reached) for BCLC-0, and 1.8 months (95% CI 1.4-3.1) for BCLC-D.
CONCLUSIONS: Our clinical data from a consecutive decade-long HCC cohort support the evolution of staging and survival data in HCC management, with CP classification, portal vein tumor thrombosis, and treatment modality as key survival predictors.
METHODS: All included patients were diagnosed between 2013 and 2022. OS was assessed using Kaplan-Meier and Cox models, stratified by BCLC stage and diagnosis period.
RESULTS: A total of 1,306 patients were analyzed: 9.1% BCLC-0, 44.3% BCLC-A, 19.1% BCLC-B, 17% BCLC-C, and 10.4% BCLC-D. Median OS (mOS) for the cohort was 19.7 months (95% CI 16.9-23.0), ranging from 86.1 months (95% CI 47.6-not reached) for BCLC-0 to 2.4 months (95% CI 1.7-3.4) for BCLC-D. Poor survival was associated with Child-Pugh (CP) classification (CP-B: HR1.49, 95% CI 1.17-1.89, CP-C: HR2.45, 95% CI 1.57-3.81), and portal vein tumor thrombosis (HR1.75, 95% CI 1.19-2.58). In 2013-2017, 609 patients (46.6%) were diagnosed with mOS of 21.7 months (95% CI 18.4-25.1), while 697 patients (53.4%) in 2018-2022 had mOS of 18.9 months (95% CI 14.8-22.7). Stratified by BCLC stage, mOS in 2013-2017 ranged from 86.1 months (95% CI 41.6-not reached) for BCLC-0 to 2.9 months (95% CI 2.2-5.7) for BCLC-D. In 2018-2022, mOS was 59.8 months (95%CI 44.2-not reached) for BCLC-0, and 1.8 months (95% CI 1.4-3.1) for BCLC-D.
CONCLUSIONS: Our clinical data from a consecutive decade-long HCC cohort support the evolution of staging and survival data in HCC management, with CP classification, portal vein tumor thrombosis, and treatment modality as key survival predictors.